Generating clinical evidence for treatment and prevention options for long COVID

Nat Med. 2024 Aug;30(8):2109-2110. doi: 10.1038/s41591-024-03031-5.

Stephanie Buchholz^{1

2}, Eugenia Di Meco^{1

3}, Ewa Z Bałkowiec-Iskra^{3

4

5

6}, Bruno Sepodes^{3

6

7}, Marco Cavaleri^{8

9}

¹ European Medicines Agency, Amsterdam, The Netherlands.
² Federal Institute for Drugs and Medical Devices, Bonn, Germany.
³ EMA Emergency Task Force, Amsterdam, The Netherlands.
⁴ Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
⁵ The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warsaw, Poland.
⁶ EMA Committee for Medicinal Products for Human Use, Amsterdam, The Netherlands.
⁷ Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal.
⁸ European Medicines Agency, Amsterdam, The Netherlands. [email protected].
⁹ EMA Emergency Task Force, Amsterdam, The Netherlands. [email protected].

No abstract available

Publication types